JW Cayman Therapeutics Extends Vector Supply Agreement with Juno
I'm PortAI, I can summarize articles.
JW Cayman Therapeutics Co. Ltd. has extended its Vector Supply Agreement with Juno, a subsidiary of Bristol Myers Squibb. The amendment, dated December 22, 2025, prolongs the supply of viral vectors essential for manufacturing and commercializing Carteyva®, an anti-CD19 CAR-T immunotherapy product. This extension is crucial for both commercial and clinical use of Carteyva®. The original content was published by JW Cayman Therapeutics via the Hong Kong Stock Exchange's Issuer Information Service.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments